New drug combo shows promise for tough cancers
NCT ID NCT01334073
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This early-stage study tested a combination of two drugs, axitinib and everolimus, in 19 people with advanced solid tumors, especially kidney cancer. The main goal was to find the safest dose and identify side effects. Participants had already tried or could not use standard treatments. The study was completed and focused on controlling the disease rather than curing it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Professeur Alain RAVAUD
Bordeaux, 33000, France
-
Professeur Jean-Pierre DELORD
Toulouse, 31000, France
Conditions
Explore the condition pages connected to this study.